Sarepta Slashes 500 Jobs, Stock Plummets 35% After DMD Gene Therapy Setbacks

Introduction

Sarepta Therapeutics Inc (NASDAQ: SRPT) is a public biotechnology company headquartered in Cambridge, Massachusetts. Founded in 1980 as AntiVirals Inc. and renamed in 2012, Sarepta specializes in precision genetic medicines for rare diseases, primarily focusing on Duchenne muscular dystrophy (DMD) and other neuromuscular disorders.

Corporate Structure

As of 2025, Sarepta employs between 501 and 1,000 individuals across its research facilities in Cambridge and the Genetic Therapies Center of Excellence in Columbus, Ohio. The senior leadership team consists of experienced professionals overseeing the company's objective to facilitate the timely development of therapies and enhance gene therapy manufacturing capacity.

Biotechnology by Louis Reed

Recent Developments and News

On November 3, 2025, Sarepta announced its third-quarter financial results for 2025 and confirmed the completion of its ESSENCE confirmatory study. The company presented new data from its neuromuscular portfolio at the 30th Annual International Congress of the World Muscle Society held in Vienna from October 7 to 11, 2025.

In July 2025, Sarepta reported a reduction of approximately 500 employees, accounting for around 36 percent of its workforce, following two patient deaths associated with its DMD gene therapy, ELEVIDYS. This restructuring initiative aims to achieve $400 million in cost savings by 2026.

As of August 15, 2025, Sarepta disclosed its pipeline, which includes one market-approved gene therapy and three RNA-based therapies in the United States.

Financial and Strategic Analysis

• Stock Price and Trading Metrics (as of November 4, 2025)
– Last traded: $15.73, down 35.66 percent on NASDAQ
– Volume: 1,335,712 shares
– 52-week range: $10.42–$138.81

• Market Capitalization and Valuation
– Market cap: $2.34 billion
– Enterprise value: $2.89 billion
– Price/sales (ttm): 0.99
– Price/book (mrq): 1.72

• Profitability and Cash Flow (ttm)
– Revenue: $2.48 billion
– Net income: –$57.96 million
– Diluted EPS: –$0.68
– Profit margin: –2.34 percent
– Total cash (mrq): $800.14 million
– Total debt/equity (mrq): 100.51 percent
– Levered free cash flow: –$257.1 million

• Equity Research and Ratings
– Investment rating: SELL
– Consensus target price: $19.00
– Subratings: Industry (Medium), Management (Low), Safety (Low), Financial Strength (Low), Growth (Low), Value (High)

Strategically, Sarepta focuses on scaling its manufacturing capabilities to address challenges in gene therapy production. The completion of the ESSENCE study and data presentations are intended to support regulatory filings and strengthen the market positioning for DMD therapies.

Market Position and Industry Context

Sarepta operates within the rare-disease segment of biotechnology, competing with established pharmaceutical companies and emerging biotech firms that focus on genetic and RNA-based therapies. Its beta of 0.50 over the past five years indicates lower volatility compared to the broader market. The company's collaborations with payers on pricing strategies and partnerships—such as the licensing agreement with Roche in 2019 for SRP-9001 outside the United States—highlight efforts to expand access to its therapies. Key factors influencing Sarepta's competitive landscape include regulatory approvals, patent terms, and outcomes of clinical trials.

tl;dr

On November 3, 2025, Sarepta reported its third-quarter results and completed its ESSENCE confirmatory study. The company plans to reduce its workforce by 500 positions by the end of 2025 to secure $400 million in savings by 2026 following two patient fatalities associated with ELEVIDYS. As of November 4, 2025, SRPT closed at $15.73 (–35.66 percent), with a market cap of $2.34 billion, net income of –$57.96 million (ttm), and $800 million in cash on hand. Upcoming catalysts include regulatory filings for DMD gene therapies, anticipated cost reductions, and data updates from the World Muscle Society Congress.